Hazardous Drug Sample Analysis
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Defense Health Agency, through its Medical R&D Contracting Division 2, has awarded a Firm Fixed Price contract for Hazardous Drug Sample Analysis under solicitation number HT942726QE008, with a period of performance from 1 May 2026 to 30 April 2027, and an option to extend for up to six additional months. The contract requires the contractor to perform exactly 200 hazardous drug sample analyses in accordance with the Performance Work Statement and Quality Assurance Surveillance Plan, adhering to ISO/IEC 17025 standards, validated laboratory SOPs, and DCPH-A approved methods. All sample analyses must include spiked Laboratory Control Samples and LCSDs, with any QA/QC failures documented and corrected promptly. The work is performed at the Defense Centers for Public Health – MM in Aberdeen Proving Ground, Maryland, where final inspection and acceptance are conducted by the Government. The contractor must be externally accredited for all listed hazardous drugs, report any changes to accreditation within five business days, and designate a qualified Quality Manager and Program Manager who are subject to annual revalidation. Compliance with cybersecurity requirements under DFARS 252.204-7012 and 252.204-7008, as well as supply chain prohibitions such as those related to the Xinjiang Uyghur Autonomous Region and the Maduro regime, is mandatory. All personnel must meet Personal Identity Verification requirements, and the contractor is responsible for safeguarding government property and information. Invoicing must be submitted exclusively through Wide Area WorkFlow, with payments processed by the DoDAAC HQ0490 at the designated remittance address. The solicitation was evaluated on a best value tradeoff basis, prioritizing Technical Approach, Past Performance, and Price, with unacceptable risk ratings leading to disqualification. The contract includes a Surge CLIN for unexpected volume increases and imposes liquidated damages of 5% per day, capped at 100%, for late or deficient data packages. Proposals were required in two separate volumes—Technical and Price—submitted electronically by 11:00 AM EST on 24 April 2026, adhering to strict formatting guidelines including a 30-page limit for the technical volume, 12-point Times New Roman font, and uncompressed file formats. The contracting officer is Jessica E. Greene, with Jennifer S. Bassett as the primary point of contact
General Info
Contract Value
$60,000Place of Performance
Aberdeen, MD, USASet-Aside
Awardee
EUROFINS ANALYTICS, LLCAward Issued Date
Timeline
Organization & Contact Information
Full Description
*******************************************************
***UPDATE - AMENDMENT #1***
The Purpose of this Amendment is to Provide Answers to Questions.
QUESTION #1 - The workload breakdown in the PWS (page 8) is structured simply by the number of drugs per sample batch, can you provide the specific drug types for each?
ANSWER #1 - A.) The PWS lists 6 possible Hazardous Drugs that a client could request. These are the only 6 requested at this time in any combination. They are: 5-Fluorouracil, Methotrexate, Ifosfamide, Cyclophosphamide Monohydrate, Doxorubicin Hydrochloride, and Paclitaxel.
B.) For Example, when a client wants "2" drugs reported, it could be a combination of any 2 of the above. One Client could request Methotrexate and Paclitaxel. Another Client could request 5-Fluorouracil and Ifosfamide. Both are only requesting "2" but the actual drugs are net set. Historically, 17 clients only wanted 1 drug reported for each sample. (each one though could have been unique)
QUESTION #2 - Is the Government or the Contractor to supply the wipes?
ANSWER #2 - The Government will supply the wipes.
QUESTION #3 - Please confirm that the government will be taking the samples and not the Contractor's technicians (i.e., the contract is 'lab only').
ANSWER #3 - The client (government) will collect the samples; nothing would be collected by the contract lab.
********************************************************
As part of the DCPH-A mission, the Lab Sciences (LS) Directorate requires the analysis of wipe/swab samples for the presence of hazardous drugs in support of pharmacies and Military Treatment Facilities (MTFs) within the Department of War (DoW). This analysis is mandated for the MTFs using Chemotherapy drugs to ensure their cleaning procedures are effective to ensure safety of the MTF staff and to avoid cross-contamination. The directives that mandate this semi-annual testing requirement are United Stated Pharmacopiea (USP) 800: Handling Hazardous Drugs and Technical Bulletin-Medical (TB-MED) 515: Occupational Health and Indutrial Hygiene Guidance for the Management, Use and Disposal of Hazardous Drugs. There is no acceptable level of occupational exposure to Hazardous Drugs. The LS Directorate of the DCPH-A is the only government laboratory to perform this hazardous drugs analysis as required. While LS does have the analytical capability to perform hazardous drugs analyses, as a sole source for this effort, there is a need to have back-up laboratory capability for instances of instrument down-time or over-capacity situations.
Objectives for this Requirement are as follows:
The Contractor shall perform analysis on wipe/swab samples provided by the Government for Hazardous Drugs contamination.
The Contractor shall perform the sample analysis within the stated turnaround time (TAT) identified in the Outsource Document and identified in the PWS.
The Contractor shall provide Quality wipe/swab analysis for various hazardous drugs as identified in this PWS in accordance with an accredited methodology.
The Contractor shall dispose of unused samples as prescribed by their quality manual/Standing Operating Procedures and return Government shipping containers.
The Contractor shall supply sampling media upon request.
The Contractor shall pay liquidated damages for late or deficient reporting as detailed in Section 5.of the PWS.
QUESTIONS are due by 20 April 2026 by 1pm Eastern Standard Time (EST)
QUOTATIONS are due by 24 April 2026 by 11am EST.
See the Performance Work Statement (PWS) for complete information regarding this effort.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Health Agency
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS